{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:12:28Z","timestamp":1790518348108,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41375-022-01603-3","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T15:02:43Z","timestamp":1653404563000},"page":"1926-1930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4354-592X","authenticated-orcid":false,"given":"Juliane","family":"Grimm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Bhayadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Gack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Heckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-0727","authenticated-orcid":false,"given":"Jan-Henning","family":"Klusmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"1603_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1470-2045(00)00435-6","volume":"2","author":"H Hasle","year":"2001","unstructured":"Hasle H. Pattern of malignant disorders in individuals with Down\u2019s syndrome. Lancet Oncol. 2001;2:429\u201336.","journal-title":"Lancet Oncol"},{"key":"1603_CR2","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1182\/blood-2007-10-118810","volume":"111","author":"J-H Klusmann","year":"2008","unstructured":"Klusmann J-H, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008;111:2991\u20138.","journal-title":"Blood"},{"key":"1603_CR3","doi-asserted-by":"publisher","first-page":"636633","DOI":"10.3389\/fonc.2021.636633","volume":"11","author":"J Grimm","year":"2021","unstructured":"Grimm J, Heckl D, Klusmann J-H. Molecular mechanisms of the genetic predisposition to acute megakaryoblastic leukemia in infants with Down syndrome. Front Oncol. 2021;11:636633.","journal-title":"Front Oncol"},{"key":"1603_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2019.06.007","volume":"36","author":"M Labuhn","year":"2019","unstructured":"Labuhn M, Perkins K, Matzk S, Varghese L, Garnett C, Papaemmanuil E, et al. Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome. Cancer Cell. 2019;36:123\u2013138.","journal-title":"Cancer Cell"},{"key":"1603_CR5","doi-asserted-by":"publisher","first-page":"e00633","DOI":"10.7554\/eLife.00633","volume":"2","author":"MA Kerenyi","year":"2013","unstructured":"Kerenyi MA, Shao Z, Hsu Y-J, Guo G, Luc S, O\u2019Brien K, et al. Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. eLife. 2013;2:e00633.","journal-title":"eLife"},{"key":"1603_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccr.2012.03.014","volume":"21","author":"WJ Harris","year":"2012","unstructured":"Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012;21:473\u201387.","journal-title":"Cancer Cell"},{"key":"1603_CR7","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/leu.2017.59","volume":"31","author":"N Sugino","year":"2017","unstructured":"Sugino N, Kawahara M, Tatsumi G, Kanai A, Matsui H, Yamamoto R, et al. A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers. Leukemia. 2017;31:2303\u201314.","journal-title":"Leukemia"},{"key":"1603_CR8","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/bloodadvances.2020003521","volume":"5","author":"K Kohrogi","year":"2021","unstructured":"Kohrogi K, Hino S, Sakamoto A, Anan K, Takase R, Araki H, et al. LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C\/EBP\u03b1. Blood Adv. 2021;5:2305\u201318.","journal-title":"Blood Adv"},{"key":"1603_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-019-0811-9","volume":"12","author":"Y Fang","year":"2019","unstructured":"Fang Y, Liao G, Yu B. LSD1\/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol. 2019;12:129.","journal-title":"J Hematol Oncol"},{"key":"1603_CR10","doi-asserted-by":"publisher","first-page":"13670","DOI":"10.1073\/pnas.1918307117","volume":"117","author":"TP Braun","year":"2020","unstructured":"Braun TP, Coblentz C, Smith BM, Coleman DJ, Schonrock Z, Carratt SA, et al. Combined inhibition of JAK\/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R\/CEBPA mutant acute myeloid leukemia. Proc Natl Acad Sci USA. 2020;117:13670\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1603_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00487-3","volume":"11","author":"W Fiskus","year":"2021","unstructured":"Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, et al. Superior efficacy of co-targeting GFI1\/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021;11:98.","journal-title":"Blood Cancer J"},{"key":"1603_CR12","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1097\/HS9.0000000000000054","volume":"2","author":"JS Jutzi","year":"2018","unstructured":"Jutzi JS, Kleppe M, Dias J, Staehle HF, Shank K, Teruya-Feldstein J, et al. LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone. HemaSphere. 2018;2:e54.","journal-title":"HemaSphere"},{"key":"1603_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","volume":"174","author":"W Sheng","year":"2018","unstructured":"Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell. 2018;174:549\u2013e19.","journal-title":"Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01603-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01603-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01603-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T03:27:58Z","timestamp":1656905278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01603-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01603-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.01.14.476342","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JHK has advisory roles for Bluebird Bio, Novartis, Roche and Jazz Pharmaceuticals. The other authors disclose no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}